"Project Canary " is seeking its Series E financing and is raising funds for the company's Early Feasibility Study in the U.S. which has received approval from the F.D.A.  The company has completed 6 cases in Europe and is continuing to enroll patients there.  Early results indicate a robust safety profile, Tricuspid Regurgitation reduction, annular reduction and positive right heart remodeling.  Global market size for Tricuspid is greater than $3bn.  

The Stiller Family has invested $5mm in this round; other current investors have invested greater than $1.5mm.  A strategic investor has indicated its interest at $5mm and a financial investor (a well-known VC fund) has indicated it desires to lead the round with $20mm.  This will enable the company to complete its EFS and begin its pivotal study.